NCT06671990尚未招募4 期
The CardioMEMS Vericiguat Heart Failure Trial
Finn Gustafsson0 个研究点目标入组 17 人开始时间: 2024年12月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 17
- 主要终点
- Pulmonary arterial pressure (diastolic)
研究概览
简要总结
The ARETHA trial is a national (Danish), multicenter, randomized, placebo-controlled, double-blind, cross-over, no run-in phase, phase 4, investigator-initiated clinical trial investigating the effect of vericiguat on diastolic pulmonary arterial pressure in patients with heart failure with reduced ejection fraction. Participants will receive both vericiguat and placebo with an intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide informed consent.
- •CardioMEMS implanted for clinical indication (≥ 2 weeks prior to first visit).
- •Known CHF with LVEF <45% (documented within the past 24 months by an imaging modality: echocardiography, nuclear imaging, LV angiography, or magnetic resonance imaging).
- •NYHA functional class II-IV symptoms.
- •Optimal and stable medical therapy for HF (as indicated under point 5 of exclusion criteria)
- •SBP ≥100 mmHg
- •dPAP >15 mmHg more than 8 days in the last 14 days on the CardioMEMS system.
排除标准
- •Patients in optimization phase in the CardioMEMS system or implantation of the CardioMEMs device within the past 2 weeks.
- •Recent (within 14 days) hospitalization for decompensated HF.
- •Average supine SBP <100 mmHg at the screening or randomization visit.
- •Current symptomatic hypotension
- •Recent changes (within 48 hours) in diuretic dose, recent (within 4 weeks) initiation of hydralazine, long-acting nitrates, β-blockers, ACEi/ARB or ARNi.
- •Marked variability in PA diastolic pressure during screening period.
- •Low CardioMEMS reading compliance (<75% 30 days reading compliance).
- •Concurrent or anticipated use of: o Long-acting nitrates or nitric oxide (NO) doners including isosorbide dinitrate, isosorbide 5-mononitrate, pentaerythritol tetranitrate, nicorandil or transdermal nitroglycerin (NTG) patch, and molsidomine. o sGC stimulators such as riociguat. o PDE5 inhibitors such as vardenafil, tadalafil, and sildenafil. o Intravenous inotropes.
- •Previous or planned LVAD or HTx implantation.
- •Implantation of CRT device within the previous 90 days.
- •Known allergy or sensitivity to any sGC stimulator.
- •Primary valvular heart disease requiring surgery or intervention or is within 3 months after valvular surgery or intervention.
- •Diagnosed with hypertrophic obstructive cardiomyopathy, acute myocarditis, amyloidosis, sarcoidosis, or takotsubo cardiomyopathy.
- •Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia
- •Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction [NSTEMI], or ST elevation myocardial infarction [STEMI] or coronary revascularization (coronary artery bypass grafting [CABG] or percutaneous coronary intervention [PCI]) within 60 days, or indication for coronary revascularization at first study visit.
- •Symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days
- •Complex congenital heart disease
- •Active endocarditis or constrictive pericarditis
- •eGFR <15 mL/min/1.73 m2 or chronic dialysis.
- •Severe hepatic insufficiency such as with hepatic encephalopathy
- •Malignancy or other non-cardiac condition limiting life expectancy to <1 years.
- •Require continuous home oxygen for severe pulmonary disease.
- •Current alcohol and/or drug abuse.
- •Participating in another interventional clinical study or plans to participate in any other trial/investigation during the duration of this study.
- •Mental or legal incapacitation and is unable to provide informed consent.
- •Immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is involved with this study.
- •Interstitial Lung Disease.
- •Is pregnant or breastfeeding (or lactating) or plans to become pregnant or to breastfeed during the course of the study.
- •Females of reproductive age and childbearing potential not using at least one safe form of contraception.
研究组 & 干预措施
Vericiguat THEN Placebo
Other
Oral vericiguat tablet (2.5, 5, and 10 mg) for first period.
干预措施: Vericiguat (Drug)
Placebo THEN Vericiguat
Other
Oral placebo tablet (2.5, 5, and 10 mg) for first period.
干预措施: Placebo (Drug)
结局指标
主要结局
Pulmonary arterial pressure (diastolic)
时间窗: From baseline to the end of treatment at 6 weeks
次要结局
- N-Terminal Pro-B-Type Natriuretic Peptide(From baseline to the end of treatment at 6 weeks)
研究者
Finn Gustafsson
Professor
Rigshospitalet, Denmark
相似试验
招募中
不适用
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"Cardiovascular DiseasesHeart FailureNCT05919342NHS Greater Glasgow and Clyde3,904
已完成
2 期
Study to Evaluate Cardiac Hemodynamics and Safety of SLV320 in Subjects With Congestive Heart FailureCongestive Heart FailureNCT00160134Solvay Pharmaceuticals
Unknown
4 期
Ability of Metoprolol to Alter the Exercise Induced Elevation of CatecholaminesHeart FailureNCT00885651Rigshospitalet, Denmark30
已完成
不适用
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure PatientsHeart Failure, CongestiveNCT00531661CardioMEMS550
已完成
3 期
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategyAcute Coronary SyndromeNCT01076764Sanofi13,220